Pharma Industry
Industry: Email Alert RSS FeedPalatin Technologies expands patent portfolio in the treatment of sexual dysfunction.
BIOTECH Patent News, November, 2004
Palatin Technologies, Inc. (Cranbury, NJ) said that the European Patent Office has allowed claims on a patent application entitled, "Compositions for Treatment of Sexual Dysfunction" (European Patent 01196184). The European patent application corresponds to Palatin's United States Patents 6,579,968 and 6,794,489 which cover the specific structure and formulation of its lead drug under development, PT-141, for the treatment of male and female sexual dysfunction. The new European and existing United States patents cover both the specific peptide used in PT-141 and use of the pharmaceutical composition for stimulating sexual response. PT-141 was developed by Palatin scientists and the patent is owned solely by Palatin.
Carl Spana, Ph.D., President and Chief...
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Most Recent Technology Articles
- INTERVIEW WITH BEN BUTTERS, DIRECTOR OF EUROPEAN AFFAIRS AT EUROCHAMBRES : "A PERFECT ROAD MAP FOR EU CLUSTERS DOES NOT EXIST".
- AGENDA.(Brief article)(Conference notes)
- FIGHT AGAINST INTERNET PIRACY.
- INTERNET : AUTHORS' SOCIETIES URGE ACTION AGAINST PIRACY.
- TELECOMMUNICATIONS : BUSINESSEUROPE HOSTILE TO FURTHER CONTRACTUAL OBLIGATIONS.(Brief article)
Most Recent Technology Publications
Most Popular Technology Articles
- What is precision air conditioning and why is it necessary?
- Business process re-engineering in the small firm: A case study
- 3G: naughty or nice? PhoneErotica.com generates over 300 million hits per month, and rings up more minutes of use per month than MSN
- BizRate to monitor in-store customer satisfaction for Office Depot stores - Market Intelligence
- Speed control of separately excited DC motor
